Skip to main content

Biden looks to push ‘reshoring’

11th June 2021

Submitted by:

Andrew Warmington

The Biden administration has announced plans to tackle the US’s dependency on imports for critical medicines, with a new strategy that will seek to drive the ‘reshoring’ of some manufacturing. This follows a multi-industry review of key supply chains, occasioned by an executive order in February.

The Department of Health & Human Services (HHS) has been tasked with establishing a public-private consortium to produce critical drugs in the US, using its powers under the Defense Production Act and existing partnerships. In the first instance, the consortium will identify 50 to 100 drugs from the FDA’s essential medicines list for prioritisation.

The HHS will also invest around $60 million from the American Rescue Plan to create “novel platform technologies” for domestic API production. These could include 3D printing and continuous manufacturing, which the FDA has been advocating for years. Other agencies have been called on to increase funding of advanced manufacturing technologies for the production of supportive care fluids, APIs and finished dosage form.

Further planned measures include the creation new authorities to help track API sourcing, as well as production on a facility-by-facility basis. Under this, the origin of all drug ingredients and finished drugs would have to be identified on the label.

Currently, an estimated 87% of the generic drugs the US uses are imported and imports are part of 90% of prescriptions filled there. The exact figure is unknown, because much of the relevant information is proprietary. The COVID-19 pandemic has thrown the issue into focus, especially in the wake of hostility to China. Indeed, considerably more stringent bills have been introduced into Congress.

However, the pharma industry has warned that the administration’s aims will not be easy to achieve, because of the cost advantages that drove manufacturing abroad in the first instance. Pharmaceutical Research & Manufacturers of America (PhRMA) stated: “While we support efforts to foster more manufacturing in the United States, moving all manufacturing here is impractical and likely not feasible”. Instead, policymakers should “take a long-term, more holistic look at global pharmaceutical manufacturing supply chains before jumping to rash proposals that may cause significant disruptions to the US supply of medicines”.

The administration has already been investing in domestic production of COVID-19 drugs. In April, the Biomedical Advanced Research & Development Authority (BARDA) signed a $354 million deal with Phlow Corporation to produce essential medications at Virginia Commonwealth University’s Medicines for All Institute.

The total cost of this could reach $812 million over ten years. Phlow and its partners, which include Ampac Fine Chemicals, producing APIs its own site in Virginia, will make COVID-19 treatments. Later, they will create an infrastructure to continue manufacturing essential medicines that are in short supply for domestic use. Over time, they intend to create the first ‘Strategic API Reserve in the US’.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington